Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Retained Earnings (2022 - 2025)

Historic Retained Earnings for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to -$1.3 billion.

  • Axsome Therapeutics' Retained Earnings fell 2190.11% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 2190.11%. This contributed to the annual value of -$1.1 billion for FY2024, which is 3437.36% down from last year.
  • Axsome Therapeutics' Retained Earnings amounted to -$1.3 billion in Q3 2025, which was down 2190.11% from -$1.2 billion recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Retained Earnings ranged from a high of -$448.8 million in Q1 2022 and a low of -$1.3 billion during Q3 2025
  • Moreover, its 4-year median value for Retained Earnings was -$835.6 million (2023), whereas its average is -$844.9 million.
  • Per our database at Business Quant, Axsome Therapeutics' Retained Earnings tumbled by 4877.02% in 2024 and then plummeted by 2190.11% in 2025.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Retained Earnings stood at -$596.3 million in 2022, then crashed by 40.12% to -$835.6 million in 2023, then plummeted by 34.37% to -$1.1 billion in 2024, then decreased by 13.77% to -$1.3 billion in 2025.
  • Its last three reported values are -$1.3 billion in Q3 2025, -$1.2 billion for Q2 2025, and -$1.2 billion during Q1 2025.